enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Consensus PT from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned a consensus rating of "Buy" from the seven research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on the stock in the last year is $33.67.

ENGN has been the topic of a number of research reports. Oppenheimer reiterated an "outperform" rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reiterated an "overweight" rating and set a $40.00 target price on shares of enGene in a research report on Wednesday, September 11th.

enGene Trading Up 3.2 %

ENGN traded up $0.25 during trading on Monday, reaching $8.15. 225,989 shares of the company's stock were exchanged, compared to its average volume of 111,133. enGene has a one year low of $4.42 and a one year high of $18.40. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $7.52 and a two-hundred day moving average price of $8.97.

enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05. Equities research analysts expect that enGene will post -1.54 earnings per share for the current fiscal year.

Insider Buying and Selling at enGene

In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the firm's stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $5.70 per share, with a total value of $57,000.00. Following the transaction, the chief executive officer now owns 10,000 shares in the company, valued at $57,000. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other enGene news, major shareholder Growth Opportunities F. Forbion purchased 41,639 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $5.97 per share, with a total value of $248,584.83. Following the acquisition, the insider now owns 2,059,459 shares in the company, valued at approximately $12,294,970.23. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the acquisition, the chief executive officer now owns 10,000 shares in the company, valued at $57,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is currently owned by company insiders.

Institutional Trading of enGene

Hedge funds have recently modified their holdings of the company. Wolverine Asset Management LLC purchased a new stake in shares of enGene during the 3rd quarter worth approximately $37,000. Altitude Crest Partners Inc. bought a new stake in enGene in the first quarter worth $2,039,000. SR One Capital Management LP bought a new stake in enGene in the second quarter worth $4,715,000. Logos Global Management LP lifted its position in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in enGene in the first quarter worth $17,095,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.